IL-10 is overexpressed in human chronic lymphocytic leukemia (CLL), and is an autocrine growth factor involved in
Introduction
Controversy exists concerning the role of interleukin 10 in B-1 malignancies. A recent report measuring the serum levels of IL-10 found that IL-10 was significantly increased in patients with chronic lymphocytic leukemia (CLL) and poor prognosis was related to IL-10 levels. 1 In an earlier report other groups also found increased IL-10 in CLL and suggested that IL-10 may be implicated in the increase in ICAM expression. 2 In some reports, IL-10 levels varied in the CLL patient population. 3 Although IL-10 may be a poor prognostic factor, not all CLL patients produce IL-10 and some studies suggest that in CLL, IL-10 may even induce apoptosis 4 but other studies found that in Stage 2 and beyond IL-10 prevents apoptosis. 5 CLL cells when removed from their in vivo environment readily undergo apoptosis and agents such as theophylline and cAMP-inducers can induce apoptosis, which is not due to any action of IL-10. 6 Evidence exists that IL-10 may prevent apoptosis but this does not seem to be through a bcl2-mediated pathway since bcl2 is not modulated by IL-10. 7 Experiments described in this paper explore the role of IL-10 on proliferation and apoptosis in a murine model of CLL.
IL-10 has been shown to play an important role as a mediator of the Th2 immune response. [8] [9] [10] Since the initiation of immune responses pertains to activation of immune cells, it is therefore not surprising that IL-10 would affect cell cycle progression. 11, 12 In this study we investigated the role of IL-10 in a disease condition in which activation of B lymphocytes results in malignancy. CLL is the most common form of adult leukemia in the Western world and is characterized by malignant expansion of B-1 cells. 13, 14 B-1 cells, a sub-population of B cells, are characterized by the surface expression of CD5, and B220 molecules. 15, 16 Unlike conventional B-2 cells, B-1 cells secrete mostly IgM natural antibodies and are thus believed to play an important role in the innate immune response. [17] [18] [19] The ability of B-1 cells to self-proliferate and their propensity to undergo anti-IgM mAb induced apoptosis indicate that B-1 cells are activated B-cells. 20, 21 B-1 cells produce a number of cytokines, such as IL-6, IL-10, TNF-␣, TGF-␤ and G-CSF. 22, 23 Previous studies have shown that IL-10 is a growth factor for B-1 cells, [24] [25] [26] and that IL-10 is a crucial factor in the development of B-1 malignancy in mice 22, 27 and in humans. 28 NZB mice have a genetic predisposition to develop B-1 malignancy, and are therefore used as a murine model for CLL. 29, 30 We have established a malignant B-1 cell line, LNC, which was isolated from the lymph node of a NZB mouse. 27 ASN IL-10 oligonucleotides have been shown to induce apoptosis in LNC in vivo and in vitro. 31 The signal transduction cascade initiated by the binding of dimerized IL-10 to the IL-10 receptor heterodimer is mediated by recruitment and tyrosine phosphorylation of Stat1, Stat3, and Stat5 proteins by Jak and Tyk2 kinases. 32 The Stat proteins form homo-and heterodimers that are translocated into the nucleus and interact with specific promoter elements, and therefore modulate downstream gene expression. 33, 34 Studies have shown that IL-10 is also involved in cell cycle progression, consistent with the role of IL-10 in acti-vation of immune cells. 11, 12 The antagonistic effects of IL-10 on human T cell activation was reported to be mediated through the regulated expression of p27/Kip1 and cyclin D2. 11 T cells which have been stimulated with superantigen will exit the quiescent G0 stage and progress through the cell cycle. G0 exit requires both the downregulation of p27/Kip1 and the upregulation of Dtype cyclins to initiate Rb phosphorylation. The addition of IL-10 blocks the downregulation of p27/Kip1 protein in T cells stimulated with the superantigen, staphylococcal enterotoxin B (SEB).
11 Additional IL-10 also abrogated cyclin D2 induction by SEB activation. Thus, IL-10 functions to prevent both the downregulation of a cell cycle inhibitor as well as the induction of a protein required for G1 transit.
The action of IL-10 on normal B cells varies depending on the maturation stage of the cells, whether the B cells are naïve cells, germinal center (GC) cells, or memory cells. The addition of IL-10 with activation molecules, anti-IgM and anti-CD40, induces B cell proliferation. The extent of the proliferation varies according to the maturation stage of the B cells. In GC and memory B cells, proliferation is rapid. By contrast, the IL-10 induced proliferation of naïve B cells is less pronounced. 12 Concurrent with these results, the protein expression of cdk6, cyclin D3 and cyclin E proteins were induced earlier in GC and memory cells compared to naïve cells. 12 As a response to proliferative signal, p27/Kip1 protein expression was also altered. 12 We have employed antisense oligonucleotides to study the cell cycle effects of IL-10 in malignant B-1 cells to further understand the role of IL-10 in the development and proliferation of B-1 cells. We demonstrated that ASN IL-10 oligonucleotides induced apoptosis in malignant B-1 cells and reduced the population of G0/G1 cells, thus elevating the percentage of cells in S phase and G2/M phase. The ability of ASN IL-10 to effect cell cycle progression accounts for its ability to induce apoptosis. ASN IL-10 did not affect the cell cycle or viability of cells once they had passes the G1/S checkpoint. These studies indicate that the effect of ASN IL-10 on a population of cells will vary depending upon the point in the cell cycle in which the cells are exposed to the oligonucleotides.
Results

In vivo and in vitro effects of ASN IL-10
The NZB strain is a model of CLL and the development of B-1 malignancies can readily be detected since these B-1 clones are usually aneuploid. We have previously shown that IL-10 was linked to the development of murine B cell lymphoproliferative disease. 22 Analysis of NZB backcross animals demonstrated a strong correlation between elevated IL-10 mRNA and the development of CLL. 22 To isolate the effects of IL-10 from other genetic elements present in the NZB strain, NZB IL-10 knock-out (KO) mice were generated. Spleen cells obtained from aged NZB and NZB IL-10 KO mice were subjected to flow cytometric analysis of DNA content to detect hyperdiploid cells characteristic of malignant B-1 clones (Figure 1 ). These mice were at least 9 months of age since the development of malignant B-1 clones is agedependent. As expected, aneuploid peaks are detected in NZB wild-type (WT) spleens, but infrequently in NZB IL-10 KO mice (Figure 1a ) with an overall incidence of aneuploid malignant B-1 cells of 71% (5/7) in NZB and 5% (1/18) in NZB IL-10KO. Staining for surface markers confirmed that spleens from NZB mice, in which IL-10 was present, contained aneuploid clones expressing surface molecules (IgM + , CD5 + ) of B-1 lineage which were absent in the NZB IL-10KO spleen (Figure 1b) .
Malignant NZB-derived B-1 cells (LNC) can be transferred to (DBA × NZB) F1 mice, and the recipients die from the leukemia/lymphoma expansion. To determine the role IL-10 plays on an established B-1 malignancy, we transferred LNC cells into F1 mice and simultaneously administered either antisense IL-10 (ASN) or sense IL-10 (SEN) oligos to the mice. A total of 1.3 mg oligos were administered over the course of 14 days. The survival of the mice is shown in Figure 1c . ASN IL-10 successfully abrogates the fatal consequence of in vivo LNC tumor growth, while SEN IL-10 oligo fails to protect the mice. We employed MTT assay (which measures the mitochondrial activity as an indicator of cell proliferation) to study the in vitro effects of anti-sense IL-10 (ASN IL-10) on LNC cells. As previously reported, the proliferation of LNC decreased following ASN IL-10 treatment. 31 The proliferation of cells treated with sense IL-10 (SEN IL-10) remained comparable to untreated LNC cells (Figure 1d 
Cell cycle effects to ASN IL-10
In order for G0/G1 cells to accumulate in G2/M following antisense IL-10, cells must progress into S phase of the cell cycle in which DNA synthesis is initiated. In order to better understand the functional significance of the G2/M block following antisense IL-10 treatment, the incorporation of 3 H -thymidine into cells was measured as an indicator of progression into S phase. LNC cells were serum starved for 3 days in order to synchronize the cells in the G0 phase of the cell cycle (Ͼ90% G0/G1 Figure 3a ). The cells were released from serum starvation and simultaneously treated with either ASN IL-10 or SCR IL-10 oligonucleotides. Cells treated with ASN IL-10 for 3 h progress into S phase at a higher rate than cells treated with SCR IL-10 oligonucleotides (Figure 3b ). The To test this hypothesis, centrifugal elutriation was performed to sort the cells into various cell cycle fractions (Figure 3c-f) . The G0/G1 (Figure 3c ) and S (Figure 3e ) fractions were treated with either ASN IL-10 or SEN IL-10 oligonucleotides. As predicted, following ASN IL-10 treatment, the fractions containing S phase cells were not susceptible to a G2/M arrest (Figure 3f ). Only cells in the early G0/G1 treated with ASN IL-10 lead to a G2/M arrest (Figure 3d) , consistent with the hypothesis that ASN IL-10 acts on G0/G1 cells.
Kinase activity of cyclin associated complexes reflect increased entry into S phase in ASN IL-10 treated cells
The cell cycle is regulated by cyclins and associated kinases which are in turn regulated by specific inhibitors. The function of p27/Kip1 is to bind to different cyclin/cdk complexes to inhibit the kinase activity of these complexes and the progression of cells from G1 to S phase of the cell cycle. The kinase activity of cyclin containing complexes as a measure of entry into S phase was measured. In Figure 4 , protein extracts from LNC cells
Genes and Immunity treated with ASN IL-10 or SCR IL-10, were immunoprecipitated with cyclin D2, cyclin E or cyclin A antibodies. The kinase activity of the immunoprecipitated complexes were then assayed. These results indicate that kinase activities for cyclin E, D2 and A associated complexes are The cells were transfected with p27-LUC and SV40 ␤-galactosidase constructs. 24-h post-transfection, oligonucleotides were added for an additional 24 h before harvest. The relative luciferase activity was normalized to expression of co-transfected ␤-galactosidase activity. The y-axis represents the ratio of luciferase activity in treated vs control transfected LNC cells.
higher in the antisense IL-10 treated extracts compared with kinase activity of SCR IL-10 ( Figure 4a ).
Expression of cell cycle regulators in ASN IL-10 treated cells
To better understand the mechanisms of G2/M blockage and apoptosis induction by ASN IL-10 oligos, the expression of cell cycle regulators p27/Kip1, and p21/Waf in LNC cells treated with ASN IL-10 and SEN IL-10 was measured (Figure 4b and data not shown). Protein levels of p21/Waf were not significantly different between ASN IL-0 treated cells as compared to SEN IL-10 treated and untreated cells (data not shown). However, ASN IL-10 treated cells displayed a significant decrease in p27Kip1 levels as compared to control and SEN IL-10 cells (Figure 4b) . These results agree with previous studies that have shown that activity of p27/Kip1 is regulated by signaling pathways of cytokine receptors. 12, 35, 36 Interestingly, the role of p27/Kip1 in clinical progression of B lymphoma has also been reported. 37, 38 In order to further understand the mechanism of downregulation of p27/Kip1 protein expression, the Wisconsin Sequence Analysis Package (GCG, WI, USA) was employed to scan the promoter region of p27 (Genbank accession number U77915) for possible sites of Stat protein binding. A consensus binding motif for SIF (sisinducible factor) at −800 of the promoter was found. The effect of removal of IL-10 (by ASNIL-10) on the transcription of p27 promoter was assayed by transfection of a plasmid containing the luciferase gene driven by the p27 promoter (−1609 to +178) 39 into LNC cells, and subsequent addition of ASN IL-10 or SEN IL-10 into the cell culture. The luciferase activity of ASN IL-10 treated cells was reduced compared to luciferase activity of SEN IL-10 treated cells (Figure 4c ).
Discussion
In this paper, we describe the consequence of the loss of IL-10 in the development of B-1 lymphoma in NZB mice, which is a model for CLL. 29, 40 Decrease of IL-10 protein (by antisense) both in vivo and in vitro prevents the growth of the malignant B-1 cells. In addition, genetic manipulation resulting in a loss of the IL-10 gene product also eliminated malignant B-1 clones in NZB IL-10 KO mice. In vitro treatment with ASN IL-10 has a profound effect on cell cycle distribution of malignant B-1 cells and following treatment there is an arrest in G2/M phase of the cell cycle and eventual apoptosis. ASN IL-10 reduced the expression of IL-10 protein, but exogenous administration of physiologic doses of rIL-10 could not abrogate the effects of antisense IL-10 (data not shown) possibly because only endogenously derived IL-10 can be found as membrane bound IL-10. 41 In addition, only G0/G1 phase cells were sensitive to antisense IL-10, indicating that events which occur in this phase of the cycle have profound effects on the ability to progress through later stages of the cell cycle and viability.
Numerous genes have been shown to be regulated by IL-10. In some cases, IL-10 reduced gene expression, 42, 43 because of the ability of IL-10 to suppress IFN induced tyrosine phosphorylation of STAT-1 due to the action of suppressor of cytokine signaling −3 (SOCS-3) induced by IL-10's action. 42 IL-10 also has different effects on resting cells vs activated cells. 11, 12 Our data indicates that a possible avenue for the action of IL-10 may lie in the regulation of a cell cycle inhibitor, ie p27Kip1. In T cells, downregulation of p27/Kip1 is required for resting naïve T cells to exit G0 and IL-10 prevented resting T cell activation. 11 In the current study, ASN IL-10 resulted in decreased p27/Kip1 levels, alluding to a role for IL-10 in maintaining the levels of p27/Kip1. In our model system, the malignant B-1 cells are endogenously activated, and are cycling through the cell cycle in the presence of IL-10. In this case, the role of IL-10 may be to maintain the G1/S checkpoint. The loss of the IL-10 mediated G1/S checkpoint not only led to an accumulation of cells in G2/M but also to an increase in apoptosis. Therefore, IL-10 in these cells may serve to elongate the time it takes for a cell to progress from G1 through S to G2 phase of the cell cycle but also preserves the viability of the cells.
In the peripheral blood of CLL patients, there is an accumulation of malignant cells in G0/G1 and depending upon the stage of activation, IL-10 can either enhance apoptosis or survival. 5, 44, 45 In the present study antisense IL-10 treatment of malignant B-1 cells in G0/G1 initially decreased p27/Kip1 expression, induced a G2M block followed by apoptosis. The role of p27/Kip1 as a gatekeeper for the transition from G1 phase into S phase in the cell cycle is well established. 46, 47 p27/Kip1 forms a trimeric complex with cdk2/cyclinE and inhibits Rb phosphorylation, an event essential for the release of the E2F transcription factor and subsequent progression into S phase of the cell cycle. Recent reports have indicated that p27 is abnormally expressed in B lymphomas. 37, 38 Vrhovac et al 38 showed that aggressive B-CLL cells have elevated expression of p27/Kip1, and cells with higher p27/Kip1 have higher viability in vitro. This is in direct correlation with our study, in which releasing LNC cells into S phase with ASN IL-10 and decreasing p27/Kip1 expression induced apoptosis. A recent study which employs Depsipeptide to induce apoptosis in human CLL cells demonstrated that p27/Kip1 protein is downregulated, 48 demonstrating that p27/Kip1 expression does correlate with induction of apoptosis in CLL. There is a consensus binding motif for SIF (sis-inducible factor) in the promoter region of p27. Because there is an SIE (sisinducible element) site on the p27 promoter (−800, Genbank accession number U77915), p27 expression may be regulated by IL-10 via STAT binding. Constitutive signaling of STAT3 has been reported in B-1 lymphocytes. 49, 50 In our in vitro malignant B-1 cell lines that constitutively express IL-10, transcription of p27 is robust and treatment with ASN IL-10 results in reduction of p27 transcription and subsequent protein expression.
In summary, IL-10 is an important cytokine for the growth and maintenance of malignant B-1 cells. In studies currently underway, recombinant IL-10 will be administered to NZB IL-10KO mice to determine if the malignant B-1 cells will accumulate because apoptosis has been prevented. Preliminary studies toward that end have indicated that, in normal mice, short-term administration of IL-10 selectively induces proliferation of peritoneal B-1 cells (data not shown). However, recent reports indicate the presence of endogenous derived IL-10 on the cell membrane which cannot be replaced by exogenous adsorbed IL-10. 41 Thus exogenous administered IL-10 may fail to result in the maintenance of malignant B-1 clones in the NZB IL-10KO mice. In summary, this paper describes the use of antisense oligonucleotide against IL-10, an endogenous growth factor of a malignant B-1 cell line, that causes cell cycle changes which subsequently lead to apoptosis induction.
Materials and methods
Mice
Mice were housed under a sterile, germ-free environment at the UMDNJ research animal facility. NZB mice were
Genes and Immunity obtained from Jackson Laboratory (Bar Harbor, ME, USA), and heterozygous C57Bl/6 IL-10KO mice were kindly supplied by Dr Werner Muller of the Institute for Genetics, University of Cologne, Germany. The heterozygous C57Bl/6 KO mice were bred into the NZB background by successive backcrosses. The IL-10 KO genotype was verified by PCR of mice tail DNA. The NZB IL-10 KO mice were obtained by eight successive backcrosses. The mice were maintained in an isolated barrier facility and housed with autoclaved food, bedding and water. The NZBIL-10 KO mice develop colitis between 4-6 weeks of age and the majority of the mice were alive at 6 months of age. DBA × NZB F1 animals were obtained from Jackson Laboratory for in vivo antisense experiments. After transfer of our in vitro malignant B-1 cells into the mice, cochleates containing 0.5 mg of ASN IL-10 or SEN IL-10 oligos were administered i.p. into mice over the course of 14 days (total oligo 1.3 mg).
Cells
As a source of malignant B-1 cells, we used an in vitro established line, LNC 27 derived from an NZB mouse which is a murine model of CLL. 29 LNC has previously been shown to express IL-10 and following in vivo transfer to result in a fatal B-1 malignant expansion. LNC cells were cultured at 37°C and 5% CO 2 with complete media (10% FBS in IMDM (Irvine Scientific, Santa Ana, CA, USA), 1 × PSF (Bio-Whittaker, Walkerville, MD, USA) and 20 mM L-Glutamine (Life Biotechnologies, Rockville, MD, USA)). For serum starvation, cells were cultured in 1% FBS for 72 h. At the end of this period, the cells were released by centrifugation and resuspended in 10% FBS complete media.
Oligonucleotide treatment
Oligonucleotides were synthesized by Operon (Alameda, CA, USA), and were added to cells at a concentration of 20-40 M. The sequences were as follows: ASN IL-10: 5Ј CATTTCCGATAAGGCTTGG 3Ј which binds to nucleotides 315-333 on the IL-10 mRNA (GenBank accession number M37897), SEN IL-10: 5Ј CCAAGCCTTATCGG AAATG 3Ј, and scrambled (SCR IL-10): 5Ј TTTACTG GTCCAGACGGAT 3Ј. The ASN IL-10 sequence has previously been shown to demonstrate optimal decrease in IL-10 production and viability of LNC cells. 31 In some experiments, we utilized SCR IL-10 that has the same base content as ASN IL-10 in scrambled order. We have found no difference between SCR-IL-10 and SEN IL-10 when using these oligos as non-specific control.
Flow cytometry
For Propidium Iodide (PI) staining, 1 × 10 6 cells were washed with sorter buffer (1 × PBS, 1% FBS, 0.1% NaN3) and stained with hypotonic PI (0.05 mg/ml PI, 0.1 M Na Citrate, 0.1% Triton X-100). FACS data was acquired on a Becton Dickinson FACScaliber (San Jose, CA, USA) with a 488 nm argon laser. Acquisition was done using CELLQuest software (Becton Dickinson), and analysis was performed using ModFit LT software (Verity House Inc, Topsham, ME, USA). Surface staining employed goat anti-mouse IgM FITC and mouse anti-mouse Ly1.2 (CD5) bio plus strepavidin PE (Caltag, Burlingame, CA, USA). Isotype controls were analyzed in a similar manner.
Cell proliferation study
Treated or untreated LNC cells (5 × 10 4 ) in 100 l of complete media with or without oligonucleotide were deposited in triplicates wells in 96 well flat-bottomed plates. Twenty microliters of 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) (5 mg/ml in PBS) were added to each well and incubated in a 37°C incubator with 5% CO 2 for 3-4 h. The plates were then processed as described previously. 51 For detection of DNA synthesis, cultures were incubated with 10 Ci per well of 3 H methyl Thymidine for the last 3 h of culture. The cells were then harvested using a PHD Harvester model 200A (Brandel, Gaithersburg, MD, USA) and incorporation of 3 H was measured using the Beckman LS500TD beta and gamma counter (Beckman, Sommerset, NJ, USA).
Centrifugal elutriation LNC cells growing in log phase of growth were harvested, resuspended in PBS with 1 mM EDTA and subjected to centrifugal elutriation on a Beckman J6-MI centrifuge (Beckman) Flow rates for fraction collection for fractions 1-8 were 27 ml/min, 30 ml/min, 34 ml/min, 38 ml/min, 41 ml/min, 45 ml/min, 50 ml/min and 70 ml/min respectively. Identification of the cell cycle phase of each fraction was determined by flow cytometric measurement of DNA content using hypotonic PI staining.
Western blotting
) either treated for 24 h with ASN IL-10, SEN IL-10 or control were lysed with protein lysis buffer (50 mM Tris-HCl pH 7.4, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na 3 VO 6 , 1 mM DTT and proteinase inhibitor cocktail (Boehringer Manheim, catalogue number 1836153) and quantitated using the Bradford assay. 52 Following extraction and quantitation, 25-40 g of proteins were loaded on a 4-20% Tris-glycine pre-casted gels (Novex, San Diego, CA, USA), and electrophoresed in 1 × SDS running buffer and transferred to nitrocellulose membrane. The membranes were blocked for 1 h with 5% milk and TBS-TWEEN, and then incubated overnight with the appropriate primary Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:1000 in TBS-TWEEN. The antibodies used were p27 (SC-527-G), p21 (SC-471), actin (SC-1616). Following primary Ab staining, the blots were then washed and incubated with 1:2000 dilution of HRP-conjugated secondary Ab (Santa Cruz) for 1 h at room temperature, washed three times and developed with an ECL kit (Amersham Pharmacia, Piscataway, NJ, USA). Quantitation was performed with the ImageQuant software (Molecular Dynamics/Amersham).
Cyclin dependent kinase assay
Total cell extracts of LNC cells following various treatments were obtained using protein lysis buffer. Total extracts between 350-700 g were incubated with rat polyclonal anti-cyclin D2 (SC-452, Santa Cruz), cyclin E (SC-481Santa Cruz) or cyclin A (SC-751), in a total of 500 l immunoprecipitation (IP) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 50 M NaF, 0.2 mM NaVO 4 , 1 mM PMSF, 1 mM DTT) for 1 h at 4°C. Thirty microliters of agarose A/G beads (Santa Cruz) were then added, followed by an additional incubation for 1-2 h. The extracts were then washed three times with IP buffer and equilibrated three times with kinase buffer (50 mM HEPES, 10 mM MgCl, 5 mM MnCl, 1 mM DTT, and protease inhibitor cocktail). The extracts were then incubated 45 min at 37°C with 10 M ATP, 8 Ci ␥ 32 P-ATP, and 40 g histone H1 or GST recombinant Rb 1-792 which encompasses both pocket A and B, as substrate. The samples were added to 2X sample buffer (63 mM TrisHCl pH 6.8, 10% glycerol, 2% SDS, 0.0025% Bromophenol blue), boiled for 3 min, and electropheresed in 4-20% Novex pre-casted Tris-Glycine gels (Novex). The gels were dried and the bands were visualized using a phosphorimager (Molecular Dynamics model 445 SI).
P27 promoter-Luciferase assay P27-LUC was a kind gift from Dr Debbie Riley and the construct has been described previously. 39 Briefly, the PCR-product containing the p27 promoter (−1609 to +178) was ligated to the pGL-2 Basic vector (Promega, Madison, WI, USA) which contains the luciferase gene downstream from a polyadenylation signal. A construct containing the ␤-galactosidase gene with an SV40 promoter was used as a co-transfectant to assay efficiency of transfection. The constructs were transfected into LNC cells using Superfect reagent (Qiagen). Cell extracts were collected using the reported lysis buffer from the luciferase assay system (Promega) according to the manufacturer's instructions. The ␤-galactosidase activity was measured using the Galactostar system (Tropix-PE Biosystem). Luciferase gene expression was measured using a DCR-1 luminometer (Digene, Gaithersburg, MD, USA). The gene expression was normalized to ␤-galactosidase expression and to total protein as quantitated by Bradford assay.
